Appeal No. 1997-1987
Application No. 08/108,005
suggests that treatment with methyl-group donors such as
betaine and methionine could be useful in HIV infection if the
role of defective methyl-group metabolism is confirmed,
nevertheless, Surtees does not disclose or suggest
treating children with HIV-encephalitis by administering
S-adenosylmethionine salt or 5-methyl-tetrahydrofolic acid, as
recited in claim 22. Accordingly, Surtees does not make up
the deficiencies of Le Grazie, and we reverse the examiner’s
decision rejecting claims 13 through 18 and 22 through 26
under 35 U.S.C. § 103 as unpatentable over the combined
disclosures of Le Grazie and Surtees.
VII. Conclusion
In conclusion, for the reasons set forth in the body of
this opinion, we reverse the examiner’s decision rejecting
claims 13 through 18 and 22 through 26.
REVERSED
SHERMAN D. WINTERS )
Administrative Patent Judge )
)
10
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007